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Introduction
Th   e history of ideas and hypotheses about atherosclerosis 
is interesting. Th  e  inﬂ  ammatory nature of atherosclerosis 
and the involvement of immune competent cells was 
described by the Austrian pathologist Karl Rokitansky in 
the 1840s and by the pathologist and social medicine 
pioneer Rudolf Virchow somewhat later in the 1850s [1]. 
As discussed in a previous editorial [2], these two 
important persons in the history of medicine had an 
interesting argument: Rokitansky believed that the 
inﬂ  ammation in atherosclerosis was secondary to other 
disease processes, but Virchow instead suggested that 
atherosclerosis is a primary inﬂ  ammatory condition. Th  e 
relevance of this discussion to cardiovascular disease 
(CVD) and athero  sclerosis in rheumatic disease is 
obvious, and in fact both arguments were most probably 
right. Virchow clearly had a point veriﬁ   ed in an 
interesting paper based on studies of Rokitansky’s own 
arterial pathological specimens. Here, activated T cells 
and other inﬂ  ammatory and immune competent cells are 
present already at a very early stage of disease, which in 
principle adds support to Virchow’s opinions [1]. A 
recent meta-analysis indicates that rheu  matic diseases 
raise the risk of premature atherosclerosis, implying that 
inﬂ  ammatory conditions such as in rheumatic diseases 
could have secondary atherosclerosis as a side eﬀ  ect [3]. 
Both Rokitansky and Virchow were right, in a non-
mutually exclusive way.
It was not until the early 1980s that the inﬂ  ammation/
immune hypothesis in atherosclerosis surfaced [4,5], 
although Russell Ross came close 1977 with his response 
to injury hypothesis [6]. Before that, the ﬁ  eld  was 
dominated by the lipid hypothesis – attention was paid 
especially to cholesterol in the blood as a risk factor. 
Initially, it appeared that these two ideas about the nature 
of the disease contradicted each other, but now there 
appears to be consensus that both are relevant and 
nonmutually exclusive, and each probably plays a diﬀ  er-
ent role depending on patient groups.
Interestingly, statins can illustrate this dual nature of 
atherosclerosis and CVD. Statins are, from a commercial 
point of view, among the most successful medicines in 
history. In fact, they may be beneﬁ  cial not only due to the 
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© 2011 BioMed Central Ltdmechanism for which they were developed but, in 
addition, for pleiotropic eﬀ   ects including anti-inﬂ  am-
matory eﬀ  ects (caused by inﬂ  uencing prenylation among 
other processes), antioxidant eﬀ   ects, decreasing low-
density lipoprotein (LDL) oxidation, and even immune 
modulatory eﬀ  ects, decreasing MHC class 2 interaction 
with antigen [7]. Th   e Jupiter study recently demonstrated 
that statin treatment may be beneﬁ  cial for individuals 
with raised high-sensitivity C-reactive protein but 
normal LDL [8].
The nature of atherosclerosis and cardiovascular 
disease
Atherosclerosis is an inﬂ  ammatory process in large and 
middle-sized arteries, where activated monocytes/
macro  phages and T cells are present in the intima [9,10]. 
Proinﬂ   ammatory cytokines are produced by immune 
competent cells in the lesions [9-11]. In addition to 
chronic inﬂ  ammation, atherosclerosis also shares charac-
teristics with autoimmune diseases – as indicated by 
studies where adoptive transfer of β2-glycoprotein I-
reactive lymphocytes enhances atherosclerosis in animal 
models [12].
Of note, atherosclerosis per se is widespread in the 
population. Atherosclerosis has been detected in Egyptian 
mummies, and also in young adult humans. Further, and 
surprisingly, even foetal atherosclerosis in the form of 
early changes (fatty streaks) has been determined [13]. 
One could therefore debate whether atherosclerosis 
indeed is a disease and not a normal aspect of human 
aging.
Even though narrow lumens caused by noncomplicated 
atherosclerosis may be a problem in some cases, however, 
it is the development of atherosclerotic plaques into more 
complicated lesions – where ﬁ  ssures and even micro-
thrombae and eventually plaque rupture occur – that 
leads to CVD, including stroke and acute coronary 
syndrome, heart failure (as a later consequence of acute 
coronary syndrome), and claudication. One major issue 
is therefore the cause of plaque rupture. Inﬂ  ammation 
plays a major role, although the exact mechanisms are 
not known. Activation of proinﬂ  ammatory cytokines and 
chemokines are prominent features of plaque rupture. 
One interesting possibility is therefore that the 
proinﬂ  ammatory state in rheumatic disease per se may 
promote atherosclerotic plaque rupture.
An interesting development is the possibility of immu-
nisa  tion, active or passive (administering anti  bodies), 
against atherosclerosis and/or CVD. Not unexpectedly, 
LDL is a target – examples of antigens as culprits include 
apolipoprotein B peptides [14] (apolipoprotein B being 
the major carrier protein in LDL) or antigens in the phos-
pholipid moiety such as phorphorylcholine (PC). Natural 
IgM antibodies against PC (anti-PC) are negatively 
associated with human atherosclerosis [15] and low levels 
of anti-PC predict increased risk of CVD independent of 
other risk factors [16-18].
In the above-mentioned meta-analysis where rheu  matic 
disease and atherosclerosis were determined, it was 
demon  strated that there is indeed a premature athero-
sclerosis in general. In this study, cases and matched 
controls where identiﬁ  ed through systematic analysis on 
PubMed and 68 comparisons from 60 diﬀ  erent studies 
were made. Taken together, of patients included in this 
meta-analysis, 37% had rheumatoid arthritis (RA), 35% 
had systemic lupus erythematosus (SLE), 9% had systemic 
sclerosis, and 19% had other rheumatic diseases [3].
In both SLE and RA, an association between CVD and 
extent of atherosclerosis has been established [19,20]. 
Th  is association points to atherosclerosis as a major 
underlying factor in co-morbidity between rheumatic 
diseases (at least SLE and RA) and CVD.
Systemic lupus erythematosus
Since the inﬂ  ammatory nature of atherosclerosis was not 
in focus until the 1980s, it is not surprising that little 
attention was paid to associations between CVD and 
rheumatic disease. In an early report from 1976, however, 
a bimodal pattern of SLE was reported [21], According to 
this paper, in addition to early direct eﬀ  ects of SLE on 
various organ systems, a later complication was CVD [21].
Before immunosuppressive treatment was imple  men  ted, 
more acute SLE manifestations, such as nephritis, were 
often fatal. Early autopsy and angiographic studies also 
demonstrated that the prevalence of atherosclerotic 
lesions is high in SLE [22,23].
Th   e strong association between SLE and CVD has been 
ﬁ  rmly established in many reports. Th   is risk can be very 
high in some patient groups: according to one study, 
women aged 44 to 50 had a 50-times increased risk of 
myocardial infarction [24]; and an increased CVD risk in 
SLE is well documented [25]. Indeed, T-helper type 2 
cytokines have been associated with SLE and at the same 
time inhibit atherosclerosis in experimental animals [25]. 
Even though it is clear that the risk of CVD is raised in 
SLE, this possibly only applies to a subgroup of SLE 
patients. Information and advice for rheumatic patients 
in relation to CVD risk should take this possibility into 
account. Even though CVD is associated with athero-
sclerosis in SLE [20], thrombosis per se possibly adds to 
the risk [20].
A combination of traditional and nontraditional risk 
factors typically accounts for, statistically, the increased 
risk of CVD in SLE, although there are variations in 
studies – for example, in relation to the role of smoking. 
Dyslipidaemia (typically the lupus pattern with high 
triglycerides), hypertension and renal disease are in 
most studies signiﬁ   cantly associated with CVD risk. 
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phos  pholipid antibodies (aPL) are also of importance in 
SLE, aPL more than in other rheumatic diseases. LDL is 
generally recognised as a risk factor in the general popu-
lation, and LDL oxidation is believed to be of impor  tance 
due to its proinﬂ  ammatory, even toxic, eﬀ  ects and the 
uptake of oxidised LDL into the vascular wall, from 
which it is then not removed. It is therefore of interest 
that oxidised LDL in the circulation is raised in SLE 
[20,25].
A possibility deserving further study is that athero-
sclerotic plaques in SLE are more prone to rupture. We 
recently determined by carotid ultrasound that vulner-
able atherosclerotic plaques are more prevalent in SLE, 
lending support to this notion [26].
Emerging risk factors that also implicate novel 
mechanisms may play a role in SLE-related CVD. Two 
examples of this are, ﬁ  rstly, anti-PC and, secondly, the 
binding of annexin A5 and interaction with endothelial 
cells, aPL and inﬂ  ammation.
Firstly, we reported recently that low levels of anti-PC 
independently predict CVD in general and that there is a 
negative association between anti-PC levels and develop-
ment of human atherosclerosis, where high levels confer 
decreased atherosclerosis development after 5 years [27]. 
Further, low levels of anti-PC were associated with SLE in 
a nested case–control SLE study [28] – and in a new SLE 
case–control study we conﬁ   rmed and extended this 
association, low levels of anti-PC being associated with 
prevalence of atherosclerotic plaques [29].
Mechanisms by which anti-PC could be beneﬁ  cial 
include an anti-inﬂ  ammatory  eﬀ   ect whereby anti-PC 
inhibits endothelial activation caused by inﬂ  ammatory 
phos  pholipids [28]. In principle, by this anti-inﬂ  amma-
tory eﬀ  ect, low anti-PC could predispose to both athero-
sclerosis and rheumatic disease, suggesting one possible 
common underlying factor. Another mechanism could be 
decreased uptake of oxidised LDL in macrophages, which 
could lead to less atherosclerosis development [16].
Secondly, binding of annexin A5, which has anti-
thrombotic properties, is decreased in individuals with 
SLE and CVD. Th   is decreased binding is caused by aPL 
that outcompete annexin A5 binding, causing a pro-
thrombotic state. We also demonstrated that annexin A5 
is abundant in atherosclerotic plaques, at sites prone to 
plaque rupture, and suggested that this protein may 
stabilise plaques, protect endothelium and inhibit plaque 
rupture [30]. Further, pooled immunoglobulin (intra-
venous immuno  globulin; IVIG) can neutralise aPL and 
restore binding of annexin A5 [31].
Rheumatoid arthritis
Th   e risk of CVD is also increased in RA, although not as 
strikingly as in SLE [32-35]. Th  e risk varies in diﬀ  erent 
studies, which could depend on the study populations 
chosen, age and other factors, including secular trends 
for RA per se. As in SLE, a combination of traditional and 
nontraditional risk factors, including inﬂ  ammation and 
also extra-articular manifestations, appears to explain 
this increased risk [32-34,36-41].
For example, in young women a 3.6-times increased 
risk of death in coronary artery disease was reported, and 
in a population-based cohort of RA patients the 
incidence of myocardial infarction and coronary heart 
disease was 50% higher in RA [32]. Similar results were 
obtained in other studies [42], and it has been suggested 
that RA is comparable with type 2 diabetes mellitus as an 
independent risk factor for CVD [43]. As in SLE, 
traditional CVD risk factors and inﬂ  ammation-associated 
factors appear to be of major importance to explain the 
increased risk of CVD in RA [25]. Th   e risk of CVD in RA 
may be decreasing [44].
While it thus appears that CVD is increased in RA and 
SLE (and other rheumatic diseases), the exact role of 
atherosclerosis/CVD and potential underlying mecha-
nisms in RA has been less clear [25].
Th  e role of rheumatoid factor in this context is not 
known, although interestingly rheumatoid factor is often 
present in smokers. Further, it is not clear how immune 
complexes in general, or even complement, aﬀ  ect  RA-
related cardiovascular co-morbidity. Perhaps comple  ment 
could play a diﬀ  erent role depending on the disease stage.
Another interesting development in RA is the role of 
citrullinated proteins and antibodies against these. 
Recent ﬁ  ndings imply that such antibodies, increasingly 
recognised as important novel risk markers for RA, could 
also play an independent role in RA-related athero-
sclerosis and CVD, including ischaemic heart disease 
[45,46].
In an interesting paper, functional polymorphisms 
relating to MHC-molecule expression were demonstrated 
to be associated with susceptibility to RA, multiple 
sclerosis and myocardial infarction [47], suggesting 
putative common mechanisms.
While many studies including the above-mentioned 
meta-analysis support an increased prevalence of athero-
sclerosis as determined by ultrasound of carotid arteries 
[37,39,48], there are also studies where such an increase 
was not detected, either as the intima-media thickness or 
as prevalence of plaque [36]. In favour of arterial changes 
in RA (as in SLE) are studies in which endothelial dys-
function has been reported [49]. aPL and also antibodies 
against oxidised LDL are raised in RA but their clinical 
importance for CVD and atherosclerosis is not clear [50]. 
Lipid peroxidation may also play a role in RA, and 
oxidised LDL-containing foam cells have been described 
in RA synovia [51]. Further, oxidative stress is increased 
in RA and associated with atherosclerosis [52].
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which are implicated in both RA and atherosclerosis – 
although immune reactivity to heat shock proteins in RA 
appears to play a somewhat diﬀ  erent role, being protec-
tive in many cases while it appears to be unfavourable in 
atherosclerosis and CVD [53].
Dyslipidaemia is often present in RA with low high-
density lipoprotein and high triglycerides in a similar way 
as in inﬂ  ammatory and infectious diseases in general. An 
increased prevalence of potentially atherogenic, small, 
dense LDL particles were reported in RA, and LDL from 
RA patients also has an increased capacity to bind 
proteo  glycans, which most probably is an important step 
in early atherogenesis [54].
As in SLE, the role played by treatment is of potential 
importance. Corticosteroids at moderate dose (7.5 mg 
prednisolone) did not aﬀ  ect atherosclerosis, but it is still 
possible they would aﬀ   ect atherosclerosis in higher 
doses – for example, the unfavourable metabolic eﬀ  ects 
may outweigh the anti-inﬂ  ammatory properties [55]. Th  e 
role of metho  trexate has been debated, but recent 
investigations suggest such treatment with folate 
substitution could inﬂ   uence CVD risk factors in a 
beneﬁ  cial way [56].
TNF inhibition could be expected to be anti-
atherogenic since TNF has proinﬂ   ammatory and un-
favourable metabolic eﬀ  ects [20]; in line with this, in a 
mouse model of atherosclerosis, TNF inhibition decreased 
atherosclerosis development [57]. Side eﬀ   ects such as 
heart failure are implicated [58]. In humans, however, 
TNF inhibition appears to have a favourable eﬀ  ect on 
CVD [59].
Even though statins may be implicated in RA (and 
potentially other rheumatic diseases) and indeed have an 
eﬀ  ect on RA per se [60], further studies are needed before 
general recommendations should be given.
Other rheumatic diseases and atherosclerosis/
cardiovascular disease
SLE and RA in relation to atherosclerosis and CVD have 
been studied more than other rheumatic diseases. In 
psoriatic arthritis, increased atherosclerosis has been 
reported [61,62] and an increased prevalence of CVD is 
well established with risk factors comparable with those 
in RA [63]. In ankylosing spondylitis, studies indicate 
that the risk of CVD is enhanced, but perhaps less so 
than in RA and SLE. Also in ankylosing spondylitis, 
dyslipidaemia and inﬂ  ammation per se may play a role, 
and positive eﬀ   ects of TNF inhibitors are discussed 
[64-66].
In vasculitis, increased atherosclerosis has been noted 
both in Kawasaki’s disease [67] and Takayasu’s arteritis 
[68,69]. In Behçet’s disease, where vasculitis commonly 
occurs, and in Wegener’s granulomatosis, increased 
athero  sclerosis as determined by carotid ultrasound has 
also been reported [70,71].
Gout has been associated with CVD and increased 
urate levels, but urate may also have antioxidant proper-
ties that may be beneﬁ   cial under some circumstances 
[72].
Summary and conclusions
Both atherosclerosis and the risk of CVD are increased in 
rheumatic diseases, especially in SLE, and the risk 
appears to be strikingly high. Th   e underlying mechanisms 
are pro  bably related to atherothrombosis and increased 
preva  lence of atherosclerotic plaques where traditional 
and nontraditional risk factors act in concert. When 
treating patients with rheumatic disease, it is important 
to pay attention to the increased risk of CVD. Traditional 
risk factors as dyslipidaemia, hypertension, diabetes and 
smok  ing should be closely monitored and disease symp-
toms including inﬂ  ammation should be treated. Hope-
fully novel therapeutic modalities will be developed that 
target the causes of the inﬂ  ammation present in athero-
sclerotic lesions.
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